Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine - Wikidata - wikimedia - TriplyDB

Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine

Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine

http://www.wikidata.org/entity/Q34157802

about

The role of innate APOBEC3G and adaptive AID immune responses in HLA-HIV/SIV immunized SHIV infected macaques Measurements of immune responses for establishing correlates of vaccine protection against HIV Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development Human immunodeficiency virus vaccine trials Scaffold optimization in discontinuous epitope containing protein mimics of gp120 using smart libraries.Lessons learned from human HIV vaccine trials.HIV-1 vaccines: challenges and new perspectives Novel directions in HIV-1 vaccines revealed from clinical trials Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection.Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates.Enhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routes HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies.Design of lipid nanocapsule delivery vehicles for multivalent display of recombinant Env trimers in HIV vaccination Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.A combinatorial approach toward smart libraries of discontinuous epitopes of HIV gp120 on a TAC synthetic scaffold.Induction of immunity to human immunodeficiency virus type-1 by vaccination.Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies.B cell responses to HIV-1 infection and vaccination: pathways to preventing infection.The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection.Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system.Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C.Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16.How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?Evolutionarily conserved T-cell epitopes on FIV for designing an HIV/AIDS vaccine Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.In silico design of a DNA-based HIV-1 multi-epitope vaccine for Chinese populations.Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission.Breakthrough Virus Neutralization Resistance as a Correlate of Protection in a Nonhuman Primate Heterologous Simian Immunodeficiency Virus Vaccine Challenge Study.Immunoglobulin-specific responses to Chlamydia elementary bodies in individuals with and at risk for genital chlamydial infection.Neutralizing antibodies to HIV-1 induced by immunization.Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions.Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milk.Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene Importance of neutralization sieve analyses when seeking correlates of HIV-1 vaccine efficacy.The role of neutralizing antibodies in prevention of HIV-1 infection: what can we learn from the mother-to-child transmission context?

P2860

Q27305204-D61114E4-1DE1-42EB-94EF-4344FDD20789 Q28728189-A62195EA-079D-4F8E-81E0-6E087BB58855 Q28730561-48012A0D-23C0-4609-8DCD-49BB48FC3570 Q30355260-F3764851-F07B-45A4-BFED-0E1D81F08FC2 Q30424366-7C25A9B5-40AE-4AC4-A2B8-B0E3D2603D8E Q31112205-8382D62C-260A-4D49-BCDB-A50373AD917F Q33557844-B9A7B31E-2409-4F81-A6AD-287A4A4B4094 Q33577972-A9784139-E363-41C8-9C6E-67147CE25B38 Q33645528-02692C23-3D34-49A0-BC34-EF7860F1FBC3 Q33702217-F17B4CE4-4B60-4F69-BEF5-CCD554B60214 Q33712296-622A040E-F5E9-4978-9EFA-A90703AD1D56 Q33742529-6E5E0720-DB56-4BCA-946B-32F2404B3B47 Q33743758-8A79C94C-F701-4A67-8A88-97879FAD95F5 Q33753573-914455BD-4A18-4025-8275-272E6ED6F71E Q34074750-4C59A6D1-72CC-4E7C-8A8B-C06C5431D2B4 Q34204047-701B3CCE-C946-4FB4-BA8A-12AC126B4CBA Q34398542-E55CDA3D-F24D-499D-929F-F9A3EC716EDD Q34540645-2B353E27-9ED5-4969-B0FC-A0B09C4FE78C Q34593647-29FAB76A-C7CF-4E7D-8B1E-A95D21013935 Q34645502-9BD6D81D-F0B8-4EC3-BD1B-65DE44345CC9 Q34982698-A9105308-D6A1-42B5-B734-3F2027A88FE4 Q35060140-307C1EEB-2D26-43FA-A6A5-9C0147B42C9E Q35061529-49104AA2-C791-440D-BE25-C43EC0B79AC7 Q35077716-5716B333-4DA3-457B-9B34-84B8B9A0D322 Q35653703-C3123B43-725B-412E-BF30-F4B464F6062A Q35709133-69B6FEA8-5E6F-47B5-B591-29F15E2D0DC5 Q35861256-AAE0C32D-D5F8-4B7C-B135-C6788D81EC19 Q35883032-EF19BEEC-5F74-407C-9A1F-FAE2E5308B76 Q35887235-48BD5DBE-82C5-4F87-8CAD-BEDB24AE626B Q36083337-3481BBFE-781C-41B5-8170-7164EB54C59D Q36086357-4F39FAC4-AB93-4BEB-AD54-4190520CB7A6 Q36184762-076B534D-56CA-45D9-9CE3-78B826178F76 Q36334371-31274F40-AF4C-4666-A50A-E32E1E4EC478 Q36412269-B2F488CA-CB62-46E7-852D-F63DC6101F6A Q36603515-33D96B96-2E30-4D7C-AA83-041B4E0FF96F Q36707546-2CCA29F2-8C60-465B-9D77-EDC1187B8499 Q36911772-50CB9A22-1B65-4070-8612-60D107FF32C2 Q36931790-124F94B2-D84C-4753-92DE-EFFC3DBC775C Q36978467-3CF80175-AF9B-4476-A628-9C84642EF1BC Q37365618-B8F8DE87-2DDC-464E-8F8F-92325B7FFCDC

P2860

Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine

http://www.wikidata.org/entity/Q34157802

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Magnitude and breadth of a non ...... candidate HIV-1 gp120 vaccine

@ast

Magnitude and breadth of a non ...... candidate HIV-1 gp120 vaccine

@en

Magnitude and breadth of a non ...... candidate HIV-1 gp120 vaccine

@nl

type

label

Magnitude and breadth of a non ...... candidate HIV-1 gp120 vaccine

@ast

Magnitude and breadth of a non ...... candidate HIV-1 gp120 vaccine

@en

Magnitude and breadth of a non ...... candidate HIV-1 gp120 vaccine

@nl

prefLabel

Magnitude and breadth of a non ...... candidate HIV-1 gp120 vaccine

@ast

Magnitude and breadth of a non ...... candidate HIV-1 gp120 vaccine

@en

Magnitude and breadth of a non ...... candidate HIV-1 gp120 vaccine

@nl

P1433

Q34157802-D2BE2157-96C4-4FAD-BC3C-D813B8C66379

P1476

Q34157802-76FE330B-D549-41B4-A83A-CBD25AA50DA1

P2093

Q34157802-01E066B5-1D93-4026-9CD0-9156F469CB94

Q34157802-10CA1A0A-4862-473D-8A8D-351060E8D74B

Q34157802-1156D2F1-EF3B-42E5-A547-F9826BEFA371

Q34157802-1D1222C2-0699-467E-8491-AA6F2B0402C1

Q34157802-209805D1-2652-4E0C-A835-BE7DB00AB2EC

Q34157802-710E9D4A-5922-432B-9F45-27D975B4A54E

Q34157802-829F7B0E-6459-47CA-BA06-7FBC614BFAC4

Q34157802-8F664345-DEF1-4C25-B042-0300990AE7B3

Q34157802-CB244D08-A75E-4F9A-BB35-1CE51D1130BB

Q34157802-D5873591-E634-48F5-8E87-36053FDCE556

P2860

Q34157802-00A50E00-B3B2-48B6-BCC3-49E237F07177

Q34157802-0BD1EF91-97BF-4DAD-8B0B-AAC5063AE3DE

Q34157802-1459E475-F9EC-4DD1-83E9-C83F35E3CA0B

Q34157802-1AC55CA0-3523-4E9C-B46A-EC08D12DA317

Q34157802-1BAAF472-B9F8-4C06-957A-03478EB61687

Q34157802-24B23B34-D065-4DE7-8CF0-FD884FEDE1DC

Q34157802-2B089F67-5D37-4AAC-BDB3-25566683A382

Q34157802-2BCDE8E1-3947-4455-92FB-FD83C08476FA

Q34157802-2F61517A-CE4D-47B1-9B98-A8C1AF7F9761

Q34157802-2F7A2C77-8291-4648-9419-9134DB3439C9

P304

Q34157802-CBF124E2-97B5-4B0F-9551-59134C94441C

P31

Q34157802-C2C2D66A-8958-4116-9D29-D9114B107D0E

P356

Q34157802-99302E3B-39C2-46C0-BD65-0B9306C01E1C

P407

Q34157802-561DEE5A-4BD4-4594-9253-CCE9589F44ED

P433

Q34157802-B87743A1-6E7C-4E3F-9D8A-17F7FB4444C1

P478

Q34157802-A9E49455-9FD9-4220-B40F-770F29B2C04C

P50

Q34157802-2AB0EA98-B6EB-4B17-B137-1CC627B51B2B

Q34157802-38DD5053-3A0D-42AC-8174-4047FF450E6E

P577

Q34157802-1EDAF22E-9337-46A6-9BE5-CAE1027FC365

P5875

Q34157802-DABB6C79-AB0D-4DF7-9D08-C5F3DA8E8AAA

P698

Q34157802-44FEB695-D66A-4C8F-83C2-3AF5143FDD6E

P921

Q34157802-BA70610C-55D1-46AC-A502-3C72D476D738

P932

Q34157802-B9BE6902-11B6-4A20-8FA8-493607CC7561

P356

P1433

The Journal of Infectious Diseases

P1476

Magnitude and breadth of a non ...... candidate HIV-1 gp120 vaccine

@en

P2093

Allan DeCamp

http://www.w3.org/2001/XMLSchema#string

Chris Petropoulos

http://www.w3.org/2001/XMLSchema#string

Faruk Sinangil

http://www.w3.org/2001/XMLSchema#string

Isaac R Rodriguez-Chavez

http://www.w3.org/2001/XMLSchema#string

Marc Gurwith

http://www.w3.org/2001/XMLSchema#string

Mike Giganti

http://www.w3.org/2001/XMLSchema#string

Patricia D'Souza

http://www.w3.org/2001/XMLSchema#string

Peter Gilbert

http://www.w3.org/2001/XMLSchema#string

Phillip W Berman

http://www.w3.org/2001/XMLSchema#string

Steve G Self

http://www.w3.org/2001/XMLSchema#string

P2860

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial

Antibody neutralization and escape by HIV-1

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

P304

595-605

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/654816

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

202

http://www.w3.org/2001/XMLSchema#string

P50

David C Montefiori

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45099803

http://www.w3.org/2001/XMLSchema#string

P698

20608874

http://www.w3.org/2001/XMLSchema#string

P921

P932

2946208

http://www.w3.org/2001/XMLSchema#string